This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo, Catalent pulled, refiled US premerger antitrust filing April 2, triggering new 30-day wait, SEC filing says

( April 3, 2024, 22:27 GMT | Official Statement) -- MLex Summary: Obesity drugmaker Novo Holdings and Catalent — a contract development and manufacturing organization — withdrew and resubmitted their US premerger antitrust paperwork to federal authorities on April 2, restarting the 30-day merger-review waiting period. The move followed discussion of the deal with Federal Trade Commission staffers "to give the FTC additional time to review the Transactions," according to an investor disclosure form filed with the Securities and Exchange Commission.See SEC filing excerpt below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login